


ISSUE DATE June 3, 2022	EFFECTIVE DATE January 3, 2022	NUMBER 01-22-16, 05-22-05, 08-22-17, 09-22-15, 10-22-07, 24-22-10, 26-22-02, 30-22-09, 31-22-16, 33-22-14
SUBJECT Third Dose of Pediatric SARS-CoV-2 Vaccine Manufactured by Pfizer, Inc.		BY  Sally A. Kozak, Deputy Secretary Office of Medical Assistance Programs

IMPORTANT REMINDER: All providers must revalidate the Medical Assistance (MA) enrollment of each service location every 5 years. Providers should log into PROMISe to check the revalidation dates of each service location and submit revalidation applications at least 60 days prior to the revalidation dates. Enrollment (revalidation) applications may be found at: <https://www.dhs.pa.gov/providers/Providers/Pages/PROMISe-Enrollment.aspx>.

PURPOSE:

The purpose of this bulletin is to inform Medical Assistance (MA) providers that the Department of Human Services (Department) added Current Procedural Terminology (CPT) code 0073A to the MA Program Fee Schedule for the administration of a third dose of the pediatric novel coronavirus (SARS-CoV-2) vaccine manufactured by Pfizer, Inc.

SCOPE:

This bulletin applies to all physicians, certified registered nurse practitioners, certified nurse midwives, physician assistants, outpatient hospital-based clinics, independent medical surgical clinics, federally qualified health centers, rural health clinics, home health agencies, ambulance providers, renal dialysis centers, psychiatric outpatient clinics, drug and alcohol outpatient clinics, and licensed pharmacies enrolled in the MA Program who may administer SARS-CoV-2 vaccines to MA beneficiaries in the Fee-for-Service (FFS) or managed care delivery systems. Providers rendering services to MA beneficiaries in the managed care delivery system should contact the appropriate managed care organization with any billing questions.

BACKGROUND/DISCUSSION:

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

The appropriate toll-free number for your provider type.

Visit the Office of Medical Assistance Programs website at:

<https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/Contact-Information-for-Providers.aspx>

On January 3, 2022, the U.S. Food and Drug Administration amended the emergency use authorization for the Pfizer, Inc. SARS-CoV-2 vaccine to allow for a third dose of the pediatric version of the vaccine.

On January 12, 2022, the American Medical Association announced a new CPT code, 0073A, for the administration of a third dose of the pediatric SARS-CoV-2 vaccine manufactured by Pfizer, Inc. The code is distinct to the SARS-CoV-2 vaccine manufactured by Pfizer, Inc. This level of specificity offers the ability to track each vaccine, even when the vaccine product is not reported, such as when the vaccine is available at no cost.

In response, the Department added CPT code 0073A to the MA Program Fee Schedule, which may be used for dates of service on and after January 3, 2022. This code is to be used by providers in both the FFS and managed care delivery systems to enable the Department to identify the specific SARS-CoV-2 vaccines that have been administered.

PROCEDURE:

MA providers in both the FFS and managed care delivery systems are to bill for the administration of a third dose of the pediatric SARS-CoV-2 vaccine manufactured by Pfizer, Inc. to MA beneficiaries using the CPT code below.

Vaccine Manufacturer	Code	Code Description
Pfizer, Inc.	0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose

Attached is the “Addition to the Medical Assistance Program Fee Schedule: Procedure Code for the Administration of a Third Dose of the Pediatric SARS-CoV-2 Vaccine Manufactured by Pfizer, Inc., Effective January 3, 2022”. The attachment identifies the procedure code, national code description, provider type, provider specialty, place of service, pricing and/or informational modifiers if applicable, and MA fee for the procedure code for providers submitting MA FFS claims.

Federally Qualified Health Centers (FQHC) and Rural Health Clinics (RHC) are to bill with the applicable CPT codes above when a SARS-CoV-2 vaccine is administered to a MA beneficiary, including those administered to homebound beneficiaries, and no other services that constitute an encounter are rendered on that date. When a SARS-CoV-2 vaccine is administered during a billable encounter, FQHCs and RHCs are to bill procedure code T1015 to be paid their provider-specific Prospective Payment System rate, and the appropriate SARS-CoV-2 vaccine CPT code on a separate claim line for tracking purposes, with no additional payment made for the administration of the vaccine. FQHCs and RHCs may not bill the Department for, or include on their cost report, SARS-CoV-2 vaccines they receive at no

cost. FQHCs and RHCs may also not bill for the administration of the vaccine for which they will be paid by another entity to administer.

MA providers in both the FFS and managed care delivery systems who administer a third dose of the pediatric SARS-CoV-2 vaccine to a MA beneficiary who is homebound should bill procedure code M0201 along with the applicable SARS-CoV-2 vaccine administration code. For additional information related to billing for the administration of SARS-CoV-2 vaccines to a MA beneficiary who is homebound, providers should refer to MA Bulletin 01-21-04, "SARS-CoV-2 Vaccine Administration for Beneficiaries who are Homebound" for billing instructions. The bulletin may be accessed at the link below:

<https://www.dhs.pa.gov/docs/Publications/Documents/FORMS%20AND%20PUBS%20OMAP/MAB2021072901.pdf>.

Providers may access the online version of the MA Program Fee Schedule on the Department's website at:

<https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/MA-Fee-Schedule.aspx>.

For information on how licensed pharmacies enrolled in the MA Program who provide services to MA beneficiaries should bill for the administration of SARS-CoV-2 vaccines by a pharmacist, please refer to MA Bulletin 01-20-60, "SARS-CoV-2 Vaccine Administration by Pharmacists", issued December 30, 2020, at the link below:

<https://www.dhs.pa.gov/docs/Publications/Documents/FORMS%20AND%20PUBS%20OMAP/MAB2020123001.pdf>.

MA providers may also bill the MA Program for the vaccine for MA eligible beneficiaries by indicating, on the claim submission, the appropriate National Drug Code and the units dispensed for the vaccine. Providers may access the online version of the MA Drug Fee Schedule on the Department's website at: <https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/default.aspx>.

Providers may not bill the Department for administration of a SARS-CoV-2 vaccine they receive at no cost or for the administration of a SARS-CoV-2 vaccine for which they will be paid by another entity to administer.

The Pennsylvania Department of Health (DOH) Vaccines for Children (VFC) Program includes Pfizer's pediatric SARS-CoV-2 vaccine on the list of vaccines available at no cost to VFC-enrolled providers for administration to children, including MA children, under 19 years of age. MA providers are encouraged to participate in the VFC program. Enrollment information is provided in the VFC Provider Handbook which can be found on the DOH website at:

<https://www.health.pa.gov/topics/Documents/Programs/Immunizations/VFC%20Handbook%20-%20Section%202.pdf>. Additionally, in order for VFC providers to receive and administer

SARS-CoV-2 vaccines, they must sign and adhere to the requirements of the *CDC COVID-19 Vaccination Program Provider Agreement* which can be found on the CDC website at:

<https://www.cdc.gov/vaccines/covid-19/provider-enrollment.html>.

Additional information and guidance pertaining to the SARS-CoV-2 vaccines can be found at the following links:

- American Medical Association
<https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-coding-and-guidance>.
- Centers for Disease Control and Prevention
<https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html>.
- Centers for Medicare & Medicaid Services
<https://www.medicare.gov/resources-for-states/disaster-response-toolkit/coronavirus-disease-2019-covid-19/index.html>.
- Pennsylvania Department of Health
<https://www.health.pa.gov/Pages/default.aspx>.

ATTACHMENT:

Addition to the Medical Assistance Program Fee Schedule: Procedure Code for the Administration of a Third Dose of the Pediatric SARS-CoV-2 Vaccine Manufactured by Pfizer, Inc., Effective January 3, 2022

Addition to the Medical Assistance Program Fee Schedule: Procedure Codes for the Administration of the Third Dose of the Pediatric SARS-CoV-2 Vaccine Manufactured by Pfizer, Inc. , Effective January 3, 2022

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	01	183	12, 22			\$40.00	No	once per day
0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	05	050, 051	12, 99			\$40.00	No	once per day
0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	08	080	12, 31, 32, 50, 99			\$40.00	No	once per day
0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	08	081	12, 31, 32, 72, 99			\$40.00	No	once per day
0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	08	082	12, 49			\$40.00	No	once per day
0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	08	110	49			\$40.00	No	once per day

0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	08	184	12, 57			\$40.00	No	once per day
0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	09	All	11, 12, 31, 32, 99			\$40.00	No	once per day
0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	10	100	11, 12, 31, 32, 99			\$40.00	No	once per day
0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	24	All	11, 31, 32, 99			\$40.00	No	once per day
0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	24	240, 247	12			\$40.00	No	once per day
0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	26	260, 261	12, 99			\$40.00	No	once per day
0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	30	300	12, 65			\$40.00	No	once per day
0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	31	All	11, 12, 31, 32, 99			\$40.00	No	once per day

0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	33	335	11, 12, 99			\$40.00	No	once per day
-------	--	----	-----	------------	--	--	---------	----	--------------